Načítá se...

Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone

Base excision repair (BER) is an essential pathway for pancreatic ductal adenocarcinoma (PDA) survival. Attempts to target this repair pathway have failed due to lack of tumor-selectivity and very limited efficacy. The NAD(P)H:Quinone Oxidoreductase 1 (NQO1) bioactivatable drug, ß-lapachone (ARQ761...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Sci Rep
Hlavní autoři: Chakrabarti, Gaurab, Silvers, Molly A., Ilcheva, Mariya, Liu, Yuliang, Moore, Zachary R., Luo, Xiuquan, Gao, Jinming, Anderson, Glenda, Liu, Lili, Sarode, Venetia, Gerber, David E., Burma, Sandeep, DeBerardinis, Ralph J., Gerson, Stanton L., Boothman, David A.
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2015
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4658501/
https://ncbi.nlm.nih.gov/pubmed/26602448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep17066
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!